“We are highly ecstatic to have taken this progressive decision of going public. We look forward for exploring new markets and availing the benefits of going public. With nation wide visibility through NSE EMERGE Platform, we shall also create an edge over our unlisted peers, thus building a strong repute in the Industry. We thank all our team members and well-wishers who have been part of this journey,” remarked Himanshu Zota, Whole-time Director, Zota Health Care Limited.
The Company started operations in 2000 by marketing pharmaceutical products on a local level. Over the years it has built a steady position in the domestic market which can be witnessed by the growth in the revenue from domestic operations from Rs 3,200.94 lakh in 2012 to Rs 5,845.59 lakh in 2016. The Company has more than 20 marketing divisions and vast product portfolio of around 2,800 products. In addition to being vast, the product portfolio is also diversified in nature, with offerings ranging from allopathic medicine to ayurvedic to healthcare products.
The Company has applied for patent of 19 unique formulations, wherein has received approvals for registration of 6 formulations. It has taken initiatives for digital marketing strategy and have already launched a mobile application for our division―Nutravedic.com and is in process of launching another application to integrate the markets and reach customers at large. Further the Company has purchased the marketing rights of Astra-Idl Ltd. for a period of three years to strengthen the market segment of generic medicines.
Establishing a position in the domestic market, Zota health Care Limiited took next leap in 2011 by setting up its own manufacturing unit at Special Economic Zone, Surat to foray in international markets. The Company has been certified as ISO-9001:2008 and facility is well equipped with the necessary machineries and resources. For the year ended March 31, 2016, the export operations contributed 9.34% of the total revenue from operations. The Company has applied for registration in 14 countries for more than 150 products, out of which they have successfully received approvals from 7 countries for more than 30 products and are in process of obtaining remaining approvals, which will give boost to the manufacturing operations and increase export share. Currently, they manufacture capsules and tablets at the SEZ unit. Its R&D capabilities enable them to support growth strategy by developing new products and processes which in turn enhancing the products range.